Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Pegcetacoplan in Pediatric PNH
2020-001350-21Phase 2Terminated
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2020
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Primary endpoint: Pharmacokinetics of pegcetacoplan. Started Dec 2020; status: terminated.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2020-001350-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001350-21.